Connect with us

Medical Devices

Asensus Surgical Announces Purchase of Senhance Robotic System by Loginov Moscow Clinical Scientific Center

Published

on

Sept. 27, 2021 10:55 UTC

RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)– Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced that Loginov Moscow Clinical Scientific Center, located in Moscow, Russia, has initiated its Senhance® Robotic Surgery program following the purchase of a Senhance Surgical System. The installation represents the first Senhance Surgical System to be used within Russia.

“We are thrilled to be partnering with such an innovative, forward-thinking institution for our first Senhance program within Russia,” said Anthony Fernando, Asensus Surgical President and CEO. “We share a commitment to advancing patient outcomes through the use of new minimally invasive technologies and look forward to helping Loginov expand their offerings to patients.’’

Asensus Surgical’s technology platform, Senhance Surgical System, is the first of its kind digital laparoscopic platform that leverages augmented intelligence to provide unmatched performance and patient outcomes through machine learning. Senhance goes beyond the typical surgical robotic systems, providing surgical assurance through haptic feedback, eye-tracking camera control, and 3D visualization, and is the first platform to offer 3 mm instruments (the smallest instrument available in the world on a robotic surgical platform). The Senhance Surgical System is powered by the Intelligent Surgical Unit™ (ISU™). The ISU enables machine vision-driven control of the camera for a surgeon by responding to commands and recognizing certain objects and locations in the surgical field, and allows a surgeon to change the visualized field of view using the movement of their instruments. The newest ISU features expand upon these capabilities and introduce more advanced features including: 3D measurement, digital tagging, image enhancement, and enhanced camera control based on real-time data from anatomical structures while performing surgery.

“Our team has been successfully and for many years developing minimally invasive surgical technologies that help our patients fast-track a return to an active life while preserving an optimal therapeutic approach. We are ready to utilize the Senhance Surgical System as part of our therapeutic options and hope that its use will allow us to achieve even safer and more reproducible surgery outcomes and ensure that a higher number of patients enjoy favorable effects of minimal invasive surgery,” said Professor Igor Khatkov, Head of the Loginov Moscow Clinical Scientific Center.

About Loginov Moscow Clinical Scientific Center

The Loginov Moscow Clinical Scientific Center (The Loginov MCSC) is one of the largest and most innovative institutions funded by the Moscow Health Department. The Loginov MCSC is a multi-disciplinary clinical, research, and training center hosting 48 medical departments, employing around 500 doctors, and performing more than 13,000 annual operations. The Loginov MCSC is headed by Professor Igor Khatkov, a proponent of minimally invasive surgical technologies and a world leader in laparoscopic pancreatic surgery. Since its founding in July 2013, The Loginov MCSC has spent considerable resources on educational activities. The training center trains specialists in 12 medical specialties in residency and four specialties in fellowship. The center features a program for the development of robotic surgery, headed by Professor Nikolay Matveev, carried out in cooperation with the Department of Surgery of the Biomedical Faculty, Pirogov Russian National Research Medical University. To learn more please visit: https://mknc.ru/.

About Asensus Surgical, Inc.

Asensus Surgical, Inc. is digitizing the interface between the surgeon and patient to pioneer a new era of Performance-Guided Surgery by unlocking clinical intelligence for surgeons to enable consistently superior outcomes and a new standard of surgery. This builds upon the foundation of Digital Laparoscopy with the Senhance Surgical System powered by the Intelligent Surgical Unit (ISU) to increase surgeon control and reduce surgical variability. With the addition of machine vision, augmented intelligence, and deep learning capabilities throughout the surgical experience, we intend to holistically address the current clinical, cognitive and economic shortcomings that drive surgical outcomes and value-based healthcare. Learn more about Performance-Guided Surgery and Digital Laparoscopy with the Senhance Surgical System here: www.senhance.com. Now available for sale in the US, EU, Japan, Russia, and select other countries. For a complete list of indications for use, visit: www.senhance.com/indications. For more information, visit www.asensus.com.

Forward-Looking Statements

This press release includes statements relating to the Senhance Surgical System and The Loginov Moscow Clinical Scientific Center hospital initiating a program with the Senhance System. These statements and other statements regarding our future plans and goals constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control and which may cause results to differ materially from expectations and include whether the Senhance Surgical System will help Loginov Moscow Clinical Scientific Center expand their minimally invasive offerings to patients and whether the use of the Senhance Surgical System will allow Loginov Moscow Clinical Scientific Center to achieve even safer and more reproducible surgery outcomes and ensure that a higher number of patients enjoy favorable effects of minimal invasive surgery. For a discussion of the risks and uncertainties associated with the Company’s business, please review our filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 11, 2021 and our other filings we make with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the origination date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210927005065/en/

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://www.biospace.com/article/releases/asensus-surgical-announces-purchase-of-senhance-robotic-system-by-loginov-moscow-clinical-scientific-center/?s=93

Medical Devices

Paragon 28, Inc. Announces Pricing of Initial Public Offering

Published

on

Oct. 15, 2021 02:35 UTC

ENGLEWOOD, Colo.–(BUSINESS WIRE)– Paragon 28, Inc. (NYSE: FNA) (“PARAGON”), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced the pricing of its initial public offering of 7,812,500 shares of its common stock at a public offering price of $16.00 per share, for total gross proceeds of $125.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. All of the shares are being offered and sold by PARAGON. PARAGON’s common stock is expected to begin trading on the New York Stock Exchange on October 15, 2021, under the ticker symbol “FNA.” The offering is expected to close on October 19, 2021, subject to the satisfaction of customary closing conditions. In addition, PARAGON has granted the underwriters a 30-day option to purchase up to an additional 1,171,875 shares of common stock at the initial public offering price, less the underwriting discounts and commissions.

BofA Securities and Piper Sandler are acting as joint lead book-running managers for the offering. Canaccord Genuity is acting as a lead manager. JMP Securities and Needham & Company are acting as co-managers.

A registration statement relating to the shares being sold in this offering was declared effective by the U.S. Securities and Exchange Commission on October 14, 2021. The offering is being made only by means of a prospectus, copies of which may be obtained from: BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; or Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by e-mail at prospectus@psc.com, or by phone at (800) 747-3924.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211014006180/en/

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://www.biospace.com/article/releases/paragon-28-inc-announces-pricing-of-initial-public-offering/?s=93

Continue Reading

Medical Devices

Apollo Endosurgery Announces Closing of Public Offering and Exercise in Full of Option to Purchase Additional Shares

Published

on

AUSTIN, TX / ACCESSWIRE / October 15, 2021 / Apollo Endosurgery, Inc. (“Apollo”) (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today the closing of its previously announced underwritten public offering. Apollo sold 9,660,000 shares of its common stock, including 1,260,000 shares sold pursuant to the underwriters’ exercise in full of their option to purchase additional shares, at a public offering price of $7.75 per share for gross proceeds of approximately $75 million, before deducting underwriting discounts and commissions and offering expenses.

Piper Sandler, Cowen and Stifel acted as the joint book-running managers for the proposed offering. Craig-Hallum and Lake Street acted as co-managers for the offering.

The offering was made pursuant to a shelf registration statement on Form S-3, including a base prospectus, filed by Apollo with the Securities and Exchange Commission (the “SEC”), which was declared effective by the SEC on May 19, 2021. A final prospectus supplement and accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website located at www.sec.gov. Copies of the final prospectus supplement and accompanying prospectus related to the offering may be obtained from Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924 or by email at prospectus@psc.com; Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com; or Stifel, Nicolaus & Company, Incorporated, Attention: Prospectus Department, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Apollo Endosurgery, Inc.

Apollo Endosurgery, Inc. is a medical technology company focused on development of next-generation, less invasive devices to advance therapeutic endoscopy designed to treat a variety of gastrointestinal conditions including closure of gastrointestinal defects, managing gastrointestinal complications and the treatment of obesity. Apollo’s device-based therapies are an alternative to invasive surgical procedures, thus lowering complication rates and reducing total healthcare costs. Apollo’s products are offered in over 75 countries today and include the X-Tack® Endoscopic HeliX Tacking System, the OverStitch® Endoscopic Suturing System, the OverStitch Sx® Endoscopic Suturing System, and the ORBERA® Intragastric Balloon.

CONTACT:

Apollo Endosurgery, Inc.
Jeff Black, 512-279-5126
investor-relations@apolloendo.com

Darrow Associates Investor Relations
Matt Kreps, 214-597-8200
mkreps@darrowir.com

SOURCE: Apollo Endosurgery, Inc.

View source version on accesswire.com:
https://www.accesswire.com/668389/Apollo-Endosurgery-Announces-Closing-of-Public-Offering-and-Exercise-in-Full-of-Option-to-Purchase-Additional-Shares

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://www.biospace.com/article/releases/apollo-endosurgery-announces-closing-of-public-offering-and-exercise-in-full-of-option-to-purchase-additional-shares/?s=93

Continue Reading

Medical Devices

Neuvotion Secures over $1M in Seed Funding to Commercialize Neurostimulation Technology

Published

on

 

DARIEN, Conn., Oct. 14, 2021 /PRNewswire/ — Neuvotion, Inc., an early-stage medical device company developing neurostimulation products for the rehabilitation and physical therapy markets, today announced that it has received over $1M in seed funding.  The Long Island Angel Network, an organized group of individual angel investors based on Long Island, and the Good Shepherd Rehabilitation Network,  a nationally recognized rehabilitation leader, have provided the company with its first equity investment. This seed funding will be used by Neuvotion to expand its team, conduct a multi-site clinical study, and seek FDA clearance for its initial product.

Further, Neuvotion secured exclusive worldwide rights to transformative technology developed by its founder, Chad Bouton, who is a professor at the Feinstein Institutes for Medical Research at Northwell Health. “I am inspired by the prospect of helping the millions of patients who have experienced a stroke, traumatic injury, or are living with movement impairment, to reach their goals,” said Chad Bouton, Founder & CEO of Neuvotion. “We are working to commercialize NeuStim™ and other technologies so they can be used in clinical practice, and ultimately in the home to increase quality of life and independence.”

“We have been very impressed with Professor Bouton’s work and are pleased to support its commercialization through our seed investment in Neuvotion,” said Steve Winick, Managing Director of Topspin Fund and member of the Long Island Angel Network. “As a leading provider of rehabilitation services, we see tremendous clinical potential for Neuvotion’s NeuStim technology,” added Michael Spigel, PT, MHA, President & CEO of Good Shepherd Rehabilitation Network. “We look forward to serving as a foundational research partner in Neuvotion’s upcoming multi-site clinical study. We feel strongly that this technology can help transform lives for people with spinal cord injuries, strokes and other neurological conditions.”

About Neuvotion
Neuvotion (www.neuvotion-inc.com) is an early-stage medical device company developing solutions for facilitating and restoring movement to the millions of patients experiencing impairment from stroke, traumatic injury, and other conditions. Its NeuStim™ technology combines highly targeted neurostimulation and artificial intelligence to make physical and occupational therapy more effective and efficient. Neuvotion is planning a multi-site clinical study to begin next year.

About Long Island Angel Network
The Long Island Angel Network (LIAN; http://www.liangels.net/) is a New York not-for-profit corporation consisting of individual angel investors interested in financing early-stage and emerging growth companies, primarily in technology- and innovation-focused areas. LIAN screeners endeavor to select companies for presentation that they judge likely to be of the greatest interest to members, but the Network does not make investment recommendations; investors’ decisions are made individually. LIAN’s goal is to back our region’s most exciting, promising early-stage growth companies.

About Good Shepherd Rehabilitation Network
Good Shepherd Rehabilitation Network (https://www.goodshepherdrehab.org/), a nationally recognized, not-for-profit rehabilitation leader with more than 70 locations throughout Pennsylvania and New Jersey, is committed to transforming lives through expertise, innovation, and compassion. Good Shepherd provides an exceptional patient experience for all ages and stages by developing leading-edge solutions, often for complex medical situations; serving as a test site for the newest rehabilitation technologies; and inspiring hope in all we do. Headquartered in Allentown, Pennsylvania, Good Shepherd also partners with Penn Medicine to provide rehabilitation and specialty services in the greater Philadelphia area and New Jersey through Good Shepherd Penn Partners.

If you would like more information about this topic, please call Travis Millman at +1 (917) 496-3663, or email info@neuvotion-inc.com.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/neuvotion-secures-over-1m-in-seed-funding-to-commercialize-neurostimulation-technology-301399861.html

SOURCE Neuvotion

 

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://www.biospace.com/article/releases/neuvotion-secures-over-1m-in-seed-funding-to-commercialize-neurostimulation-technology/?s=93

Continue Reading

Medical Devices

FEops HEARTguide Authorized by FDA for Unprecedented LAAo Planning Capabilities

Published

on

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211014005139/en/

“The pre-operative insight provided by FEops HEARTguide™ is powerful and can help me to optimize decision making for selecting optimal device size and position,” said Dr Jacqueline Saw, Vancouver General Hospital, Canada. “FEops HEARTguide™ is an intuitive platform I can use to discuss cases with the entire heart team to streamline my pre-op planning workflow.”

“FDA authorization of FEops HEARTguide™ is a significant milestone as this is the first Interventional Cardiovascular Implant Simulation Software Device cleared on the US market,” said Peter Mortier, PhD, co-founder and CTO of FEops. “Research on this technology began more than 10 years ago. We have continued to develop it with the goal of helping healthcare professionals identify the most appropriate treatment strategy for each patient precisely, safely and efficiently. This De Novo clearance is only a first step, and we are already preparing for FDA 510(k) submissions for FEops HEARTguide™ LAAo workflow with Abbott’s Amplatzer™ Amulet™ device and Boston Scientific’s WATCHMAN FLX™ device.”

*The Owner/Operator Number for this Registration is: 10082838 and the listing number: DEN200030.

FEops HEARTguide™ is a one-in-its-kind procedure planning platform for structural heart interventions that provides physicians with unique insights to evaluate device sizing and positioning pre-operatively. The platform uses digital twin technology based on patient-specific virtual replicas of the heart. Besides the recent FDA clearance to enter the US market with its LAAo workflow with WATCHMAN™, FEops HEARTguide™ is also commercially available in the European Union, UK, Canada and Australia for its TAVI and LAAo workflows.

About FEops HEARTguide™

FEops HEARTguideTM cloud-based procedure planning environment uses digital twin technology to provide clinicians and medical device manufacturers with first-ever insights into the interaction between transcatheter structural heart devices and specific patient anatomy – pre-operatively. Additionally, this includes also a range of quality controlled, validated and AI-enabled** anatomical analyses. Such insights have the power to help ultimately to improve clinical outcomes in real-world hospital settings, as well as to accelerate research and development of novel device-based solutions.

** Currently available only in the European Union, UK, Canada and Australia for its TAVI and LAAo workflows.

About FEops

Privately held FEops, headquartered in Gent, Belgium, is a digital health player offering cloud-based procedure planning solutions in the structural heart space combining digital twin and AI technologies. In September 2017, FEops announced that it closed a 6 million euros financing, led by Valiance, and joined by existing investors Capricorn Partners and PMV. In December 2019, FEops has been awarded a grant of Euro 3.2 million from the European Innovation Council (EIC) accelerator programme.

www.feops.com

PlatoAi. Web3 Reimagined. Data Intelligence Amplified.
Click here to access.

Source: https://www.biospace.com/article/releases/feops-heartguide-authorized-by-fda-for-unprecedented-laao-planning-capabilities/?s=93

Continue Reading
Blockchain1 day ago

People’s payment attitude: Why cash Remains the most Common Means of Payment & How Technology and Crypto have more Advantages as a Means of payment

Fintech4 days ago

PNC cuts nearly 600 apps for BBVA conversion

Automotive4 days ago

This Toyota Mirai 1:10 Scale RC Car Actually Runs On Hydrogen

Automotive2 days ago

7 Secrets That Automakers Wish You Don’t Know

Blockchain2 days ago

What Is the Best Crypto IRA for Me? Use These 6 Pieces of Criteria to Find Out More

Startups1 day ago

The 12 TikTok facts you should know

Gaming2 days ago

New Steam Games You Might Have Missed In August 2021

IOT2 days ago

The Benefits of Using IoT SIM Card Technology

Blockchain2 days ago

The Most Profitable Cryptocurrencies on the Market

Esports4 days ago

New World team share details of upcoming server transfers in Q&A

Gaming2 days ago

How do casinos without an account work?

Energy4 days ago

Segunda Conferência Ministerial de Energia da Rota e Cinturão é realizada em Qingdao

Gaming2 days ago

Norway will crack down on the unlicensed iGaming market with a new gaming law

Blockchain2 days ago

What does swapping crypto mean?

Esports5 days ago

How TFT Set 6 Hextech Augments work: full list and updates

Gaming2 days ago

Norway will crack down on the unlicensed iGaming market with a new gaming law

Supply Chain20 hours ago

LPG tubes – what to think about

Energy4 days ago

People’s Daily Online: uma pesquisa do Instituto de Zoologia de Kumming mostrou um aumento estável da população de pavões verdes, uma espécie ameaçada de extinção

Esports4 days ago

How to play Scream Deathmatch Game Mode in Call of Duty: Black Ops Cold War

AR/VR2 days ago

Preview: Little Cities – Delightful City Building on Quest

Trending